BREVITY:A phase II study of brentuximab vedotin using a response adapted design in patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity

Trial Overview and Summary

This trial is looking at a drug called brentuximab for people with Hodgkin lymphoma who are too unwell to have chemotherapy.

Doctors usually use chemotherapy to treat Hodgkin lymphoma (HL). But some people are too unwell to have this type of treatment, or have another medical condition which means they cannot have chemotherapy.

Researchers know that Brentuximab has been helpful for people whose HL has come back after chemotherapy treatment. So they think this drug may help people who can’t have chemotherapy. They also think it may have fewer side effects.

Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible

Chief Investigator:  Professor John Radford
Sponsor:  University of Birmingham
Funders:  TAP Bloodwise
Disease Site:  Hodgkin’s lymphoma
Trial Type:  Clinical Trial of an Investigational Medicinal Product
Status:  Follow-up
UKCRN Study ID: (if applicable)  14703
Open to new sites?  No
Recruitment start date:  Jan 2014
Anticipated Recruitment end date  Oct 2015
CRCTU Trial Management Team:  Haematology
Trial E-mail Address:

Trial Protocol

Please Note:

Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial. Patients who are interested in taking part in the trial are advised to talk to their health care professional or refer to CancerHelp website.

Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference.